From allusions in Alice in Wonderland to subject matter in Ted Talks, psychedelics are moving from pop culture parody toward mainstream medicine. What challenges does this evolution pose for the pharmaceutical community? Panelists will explore regulatory uncertainty, including psychedelics as a Schedule I drug and efficacy; patient safety data gaps; potential benefits of use; and cultural significance of psychedelics to many Indigenous people and the importance of those roots as psychedelics are developed for pharmaceutical purposes. 

Get Access

  • +$100 for nonmembers


Commander Gene Gunn, Bioresearch Monitoring Specialist, FDA and US Public Health Service
Robert Haferd, Restorative Justice Coordinator, Office of the Attorney General of the District of Columbia
Karen Luong, Litigation Attorney, Husch Blackwell LLP
Moderated by Deborah Miran, DMiran Consulting

Virtual Learning FAQ

On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.


On-demand content can be played back on most devices.


CLE credit is not currently available for pre-recorded sessions.

Related Content